EN DE
Watch Acarix A/S for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Acarix A/S (ACARIX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Acarix A/S stock SEK 0.03, price SEK 0.17, that is 81.9% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0009268717

AA Acarix A/S logo Thin data Nov 3, 2026

Acarix A/S

ACARIX · ST
Very expensive, weak quality

Our calculation puts a fair price 82% below what the stock costs today.

Revenue last quarter +103% vs. a year ago.
Mixed Growth (revenue 5y +27.7 %/yr in SEK)
Fair value kr 0.0300 · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 10/100 · thin data
Thin data
Watch Acarix A/S for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 1.19 kr 0.1660 Fair Value kr 0.0300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range kr 0.1660 – kr 1.19 · fair‑value band kr 0.0200 – kr 0.0300 · the kr 0.1660 price screens above the kr 0.0300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Acarix A/S in your weekly email

Every Wednesday you see whether Acarix A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out.

Show moreShow less

The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care.

It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

Stock analysis

Acarix A/S (ACARIX) currently trades at kr 0.1660, while our model-based Fair Value estimate is kr 0.0300, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.0200 (bear) to kr 0.0300 (bull), the price of kr 0.1660 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Acarix A/S reported revenue of 7.4M SEK in FY2025 versus 3.8M SEK in FY2021, a compound +18.3%/yr. Reported net income was −48.1M SEK in FY2025.

Key figures

Market cap 210M SEK (≈ $21.3M) Micro · P/S ratio 24.7 · EPS (TTM) kr −0.0400 · Return on equity −86.1% · Return on assets (EBIT) −91.7% (5-year average) · Operating margin −404% · Revenue (TTM) 9.2M SEK · Revenue growth (YoY) +103%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −82%, ACARIX screens richer than that median.

Fair Value models

Bear kr 0.0200 Fair Value kr 0.0300 Bull kr 0.0300
Price kr 0.1660 · Downside -81.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.0200 kr 0.0300 kr 0.0300 53
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.0200 kr 0.0300 kr 0.0300 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 68
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 2
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,909.3% (2020) → −652.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ACARIX screens overvalued: fair value 82% below the price. Compare with Abbott Laboratories, →

Compare Acarix A/S with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −81.9% · Bottom 25%
Profitability
Return on assets −99.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 102.5% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 5.50× · Priciest 25%
P/S (12 months) 22.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs ACARIX
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs ACARIX
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs ACARIX
DexCom, Inc DXCM $79.41 $87.35 +10% vs ACARIX
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs ACARIX
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs ACARIX
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs ACARIX
Abbott Laboratories, ABT $109.93 $75.28 −32% vs ACARIX
Medtronic plc MDT $101.80 $65.61 −36% vs ACARIX
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs ACARIX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Acarix A/S: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Acarix A/S Fair Value". https://www.fairvalue-calculator.com/stock/ACARIX

Frequently asked questions

Is Acarix A/S (ACARIX) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of kr 0.0300 versus a price of kr 0.1660, about 82% lower (overvalued).
What is the fair value of ACARIX?
Our model-based fair value for Acarix A/S is kr 0.0300 (as of Nov 3, 2026), built from audited fundamentals. The current price: kr 0.1660.
What is the quality score of ACARIX?
Acarix A/S has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acarix A/S (ACARIX)?
Our model-based price target is the fair value of kr 0.0300 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario kr 0.0200, optimistic scenario kr 0.0300. It is a calculation from audited fundamentals, not an analyst target.
What is the Acarix A/S stock forecast for 2026?
Our models put fair value at kr 0.0300, about 82% lower versus a price of kr 0.1660 (overvalued). Cautious scenario kr 0.0200, optimistic scenario kr 0.0300. The calculation is refreshed regularly with new filings.
What is the revenue of Acarix A/S (ACARIX)?
Acarix A/S reported trailing-twelve-month revenue of about 9.2M SEK (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Acarix A/S (ACARIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acarix A/S it is kr 0.0300 per share (as of Nov 3, 2026), against a price of kr 0.1660. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Acarix A/S stock overvalued or undervalued in 2026?
As of Nov 3, 2026, ACARIX trades above its calculated fair value: price kr 0.1660, fair value kr 0.0300, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACARIX?
No. The price is what the market pays today (kr 0.1660); the fair value is what the company's own numbers justify (kr 0.0300). For Acarix A/S the two are kr 0.1360 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acarix A/S worth?
The market values Acarix A/S at about 210M SEK (market capitalisation, as of Nov 3, 2026). Per share that is kr 0.1660; our models calculate a fair value of kr 0.0300 per share.
What do the bullish and bearish scenarios say about ACARIX?
Our models span a range for Acarix A/S: cautious scenario kr 0.0200, base kr 0.0300, optimistic kr 0.0300 per share (as of Nov 3, 2026, price kr 0.1660). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acarix A/S (ACARIX)?
Balance-sheet figures for Acarix A/S (as of Nov 3, 2026): return on equity −86.1%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is ACARIX from its 52-week high?
Acarix A/S trades at kr 0.1660, about 51% below its 52-week high of kr 0.3375 and at the low of kr 0.1660 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0300 is for.
Which stocks are comparable to Acarix A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acarix A/S stock attractive at the current price?
The data as of Nov 3, 2026: price kr 0.1660, calculated fair value kr 0.0300 (−82%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACARIX calculated?
We run Acarix A/S through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 0.0300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Acarix A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acarix A/S (ACARIX)?
The closing price on Nov 6, 2026 was kr 0.1660. Our model-based fair value is kr 0.0300, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acarix A/S right now?
The price sits above even our optimistic bull case (kr 0.0300). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Acarix A/S

How large is the market capitalisation of Acarix A/S (ACARIX)?
The market capitalisation of Acarix A/S is 210M SEK (≈ $21.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acarix A/S (ACARIX)?
The price-to-sales ratio of Acarix A/S is 24.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Acarix A/S (ACARIX)?
Earnings per share at Acarix A/S are kr −0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Acarix A/S (ACARIX)?
The return on equity (ROE) of Acarix A/S is −86.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acarix A/S (ACARIX)?
On an EBIT basis the return on assets of Acarix A/S is −91.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acarix A/S (ACARIX)?
The operating margin of Acarix A/S is −404% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acarix A/S (ACARIX)?
Revenue at Acarix A/S is growing +103% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acarix A/S (ACARIX) generate?
The free cash flow of Acarix A/S is −49.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acarix A/S (ACARIX) hold?
Acarix A/S holds more cash than debt, 18.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Acarix A/S in the live analysis

One click puts Acarix A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.